Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 + Inositol vs NAC in NVLD/ASD
NCT03757585Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- May 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of omega-3 fatty acid, bCalm, acetylcysteine in Autism Spectrum Disorder (ASD), Nonverbal Learning Disorder (NVLD), sponsored by Massachusetts General Hospital. Started May 2019; status: completed.
02
Drugs
omega-3 fatty acidbCalmacetylcysteine
03
Conditions
Autism Spectrum Disorder (ASD)Nonverbal Learning Disorder (NVLD)
Beyond the preview
Go deeper on NCT03757585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757585.